Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

by Paul F. Torrence

About
Antiviral Drug Discovery gives readers a cutting-edge view of how chemical concepts are being mobilized to develop novel approaches that will effectively confront emerging diseases and biowarfare. Among the many topics discussed are smallpox, the Ebola virus, influenza, SARS, arenaviruses and flaviviruses. Each chapter discusses hypothetical strategies for the discovery of relevant antiviral agents, recent findings related to biochemistry or drug discovery, and advances in the further development of established leads in the area. Timely and informative, this book clearly delineates the efforts being made to develop new and effective broad-spectrum antiviral agents.

Discuss Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats with other readers

Join or start a book club for Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats on Readfeed. Live chat, shared reading progress, and AI discussion questions — free to get started.

Frequently asked questions

How do I join a book club for Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats?

Sign up free on Readfeed, then browse public clubs or start your own club with Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats as the current read. Invite friends with a share link and discuss together with live chat and AI discussion questions.

Can I discuss Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats with other readers online?

Yes. Readfeed book clubs let you chat live, share progress, and join discussions about Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats with readers worldwide — whether your club is virtual, in-person, or hybrid.

Is Readfeed free?

Yes. Creating an account and joining book clubs is free. Sign up to find readers who love the same books and start discussing today.